Peer review

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW
Subscribe to Endpoints News

Alex Hard­ing to chase in­dus­try dreams at CRISPR Ther­a­peu­tics; Scoop: Bio­gen’s head of busi­ness de­vel­op­ment splits for Kite

While Alex Harding is a practicing physician, he’s long envisioned a career on the business side of drug development. Next year, he’s seizing an opportunity to further those goals at CRISPR Therapeutics.

The Swiss-American company announced on Monday that Harding — one of Endpoints News’ 20 under 40 honorees in 2020 — is joining on Jan. 5 as SVP and head of business development. CEO Samarth Kulkarni said in a news release that the appointment will be “critical in driving the next phase of growth for CRISPR.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Hem­genix now ap­proved, Paul Per­reault plans his ex­it from CSL; Lian­Bio pres­i­dent hands in res­ig­na­tion

→ As CSL trends upward, Paul Perreault will soon step down, putting one of his lieutenants in the top spot.

Paul McKenzie, the COO at the Australian pharma since 2019, will become CSL’s chief executive on March 6, while Perreault lends a hand in an advisory capacity for six more months after the transition takes effect. McKenzie owns Big Pharma experience from Merck, Bristol Myers Squibb and J&J’s Janssen, and was Biogen’s EVP of pharmaceutical operations & technology before CSL came calling.

Bio­gen vet jumps to CSO at Third Rock Treg biotech; Karuna CEO is step­ping down, but this is­n't good­bye

Just a few days into her new job, Ellen Cahir-McFarland’s office is being emptied.

Cahir-McFarland, formerly head of research at Annexon, is the new chief scientific officer of Abata Therapeutics, a preclinical biotech that’s developing regulatory T cell, or Treg, therapies for multiple sclerosis. On Monday, Abata will be moving from its current shared space to its new office in Watertown, MA — hence the emptying, Cahir-McFarland tells Endpoints News from a now bare, white-walled office room.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.